What are the recommendations for prescribing metformin (generic) to women with polycystic ovary syndrome, including indications, starting dose, titration schedule, target maintenance dose, monitoring of renal function, and contraindications?

Metformin Use in Polycystic Ovary Syndrome

Metformin should be prescribed as an adjunct to lifestyle interventions in women with PCOS, particularly those with elevated BMI or insulin resistance, to improve metabolic parameters, menstrual regularity, and hormonal profiles, but it is not first-line therapy for ovulation induction or weight loss alone. 1, 2, 3, 4

Indications for Metformin in PCOS

Metformin is indicated for women with PCOS in the following clinical scenarios:

• Metabolic dysfunction: Women with documented insulin resistance (elevated insulin levels on 2-hour 75g glucose tolerance test), impaired glucose tolerance, or those at risk for type 2 diabetes 5, 2, 3
• Adjunctive therapy for menstrual irregularity: To restore menstrual cyclicity and improve ovulation rates, particularly in overweight women 1, 6, 2
• Clomiphene citrate resistance: As combination therapy with clomiphene citrate in women who fail to ovulate with clomiphene alone 1, 7, 8
• Assisted reproductive technology (ART): In women undergoing long GnRH agonist protocols to reduce ovarian hyperstimulation syndrome risk and potentially improve pregnancy rates 1, 8
• Early pregnancy: Continuation through first trimester at effective doses (1000-2000 mg/day) may reduce miscarriage rates 1, 2

Important caveat: Metformin is NOT first-line therapy for ovulation induction (letrozole is superior), weight loss as monotherapy, or treatment of hirsutism/acne 2, 4

Dosing Protocol

Starting Dose

• Initial dose: 500 mg orally twice daily with meals OR 850 mg once daily with meals 9
• Starting with meals reduces gastrointestinal side effects, which occur in a significant proportion of patients 3

Titration Schedule

• Increase by 500 mg weekly OR 850 mg every 2 weeks based on tolerability 9
• Gradual titration minimizes gastrointestinal adverse effects (nausea, diarrhea, abdominal discomfort) 3

Target Maintenance Dose

• Target dose: 1500-2000 mg daily in divided doses 9, 1, 2
• Maximum dose: 2550 mg per day 9
• Doses above 2000 mg may be better tolerated when given three times daily with meals 9
• Studies in PCOS typically used 1000-2000 mg/day with demonstrated efficacy 1, 6

Renal Function Monitoring

Pre-initiation Assessment

• Assess eGFR before starting metformin 9
• Contraindicated if eGFR <30 mL/min/1.73 m² 9
• Do not initiate if eGFR 30-45 mL/min/1.73 m² 9

Ongoing Monitoring

• Assess renal function periodically during therapy 9
• If eGFR falls below 45 mL/min/1.73 m² during treatment, assess benefit-risk of continuing 9
• Discontinue if eGFR falls below 30 mL/min/1.73 m² 9

Special Circumstances

• Discontinue before iodinated contrast imaging in patients with eGFR 30-60 mL/min/1.73 m², history of liver disease, alcoholism, heart failure, or those receiving intra-arterial contrast 9
• Re-evaluate eGFR 48 hours after imaging; restart only if renal function is stable 9

Contraindications

Absolute contraindications include:

• eGFR <30 mL/min/1.73 m² 9
• Acute or chronic metabolic acidosis (risk of lactic acidosis) 9
• Hypersensitivity to metformin 9

Relative contraindications requiring careful assessment:

• eGFR 30-45 mL/min/1.73 m² (do not initiate, but may continue if already established) 9
• Conditions predisposing to lactic acidosis: severe hepatic disease, acute heart failure, sepsis, dehydration 9

Expected Outcomes and Efficacy

Metabolic Benefits

• Moderate certainty evidence shows BMI reduction (mean difference -0.53 kg/m²), improved insulin resistance (HOMA-IR reduction -0.50), and reduced fasting glucose (-0.13 mmol/L) compared to placebo 3
• Improvements in lipid profile: reduced total cholesterol, LDL, and triglycerides 3
• Studies demonstrate HOMA-IR improvement from 4.6 to 2.3 and significant reductions in 2-hour glucose levels 6

Hormonal and Reproductive Benefits

• Reduces testosterone, free androgen index, and DHEAS levels 6, 2
• Restores menstrual cyclicity in approximately 67% of women 6
• Improves acne (36% to 4%) and hirsutism scores, though not first-line for these features 6, 2
• In fertility studies, 16 of 48 women (33%) with infertility achieved pregnancy during metformin therapy 6

Combination Therapy

• Metformin + clomiphene citrate is superior to either agent alone in clomiphene-resistant PCOS 1, 8
• Metformin + letrozole is NOT more effective than letrozole alone for ovulation induction 1

Adverse Effects

• Gastrointestinal effects are common: nausea, diarrhea, abdominal discomfort (OR 7.67 for mild GI effects vs placebo) 3
• These effects are dose-dependent and typically improve with gradual titration and taking medication with meals 9, 3
• Lactic acidosis is rare but serious, occurring primarily in patients with renal impairment or other predisposing conditions 9

Pregnancy Considerations

• May continue through first trimester at effective doses (1000-2000 mg/day) to potentially reduce early pregnancy loss and miscarriage rates 1, 2
• Evidence for reducing gestational diabetes and preeclampsia is inconsistent 2
• Generally considered safe for mother and neonate, though long-term offspring effects require further study 1, 2
• Discontinue with positive pregnancy test unless specific indications exist (e.g., type 2 diabetes, high miscarriage risk) 5

Clinical Algorithm for Metformin Use in PCOS

1. Confirm PCOS diagnosis per international criteria 4
2. Assess renal function (eGFR) - do not initiate if <45 mL/min/1.73 m² 9
3. Identify primary treatment goal:
   • Metabolic improvement/diabetes prevention → Metformin indicated 5, 3
   • Ovulation induction → Letrozole first-line; metformin if clomiphene-resistant 1, 4
   • Weight loss → Lifestyle first; metformin as adjunct only 2, 3
   • Hirsutism/acne → Other therapies preferred 2
4. Initiate 500 mg twice daily with meals, titrate by 500 mg weekly to 1500-2000 mg/day 9, 1
5. Monitor renal function periodically 9
6. Reassess at 3-6 months for metabolic, hormonal, and menstrual outcomes 6, 3